| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Long Noncoding | 6 | 2025 | 218 | 2.020 |
Why?
|
| Hepatoblastoma | 8 | 2026 | 204 | 1.990 |
Why?
|
| Liver Neoplasms | 11 | 2026 | 1373 | 1.710 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2026 | 982 | 1.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2026 | 2026 | 1.220 |
Why?
|
| MicroRNAs | 11 | 2025 | 889 | 0.980 |
Why?
|
| Gene Expression Profiling | 13 | 2023 | 1801 | 0.900 |
Why?
|
| Computational Biology | 9 | 2024 | 862 | 0.690 |
Why?
|
| Transcriptome | 3 | 2023 | 1103 | 0.600 |
Why?
|
| Cell Line, Tumor | 19 | 2026 | 3748 | 0.570 |
Why?
|
| Transcription Factors | 11 | 2026 | 2406 | 0.540 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 889 | 0.520 |
Why?
|
| Gene Regulatory Networks | 6 | 2018 | 373 | 0.500 |
Why?
|
| RNA, Messenger | 8 | 2025 | 2550 | 0.490 |
Why?
|
| Neoplasms | 6 | 2024 | 3016 | 0.490 |
Why?
|
| Neuroblastoma | 4 | 2022 | 546 | 0.460 |
Why?
|
| Receptor, Notch1 | 2 | 2015 | 78 | 0.450 |
Why?
|
| Glioblastoma | 3 | 2018 | 371 | 0.440 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2015 | 57 | 0.440 |
Why?
|
| Algorithms | 11 | 2015 | 1680 | 0.430 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2025 | 21 | 0.430 |
Why?
|
| Cell Differentiation | 5 | 2026 | 1928 | 0.410 |
Why?
|
| Humans | 67 | 2026 | 131163 | 0.380 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 555 | 0.370 |
Why?
|
| Promoter Regions, Genetic | 10 | 2021 | 1207 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2024 | 614 | 0.350 |
Why?
|
| Mutation | 9 | 2026 | 6099 | 0.350 |
Why?
|
| Sequence Analysis, RNA | 5 | 2023 | 407 | 0.350 |
Why?
|
| Sequence Alignment | 3 | 2015 | 582 | 0.340 |
Why?
|
| DNA-Binding Proteins | 5 | 2026 | 1939 | 0.330 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 350 | 0.320 |
Why?
|
| Radiation Tolerance | 3 | 2025 | 61 | 0.290 |
Why?
|
| Cytokines | 2 | 2025 | 1339 | 0.290 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 92 | 0.290 |
Why?
|
| Cell Line | 8 | 2021 | 2552 | 0.290 |
Why?
|
| Oncogenes | 3 | 2018 | 164 | 0.280 |
Why?
|
| Animals | 33 | 2025 | 33912 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 6 | 2022 | 1692 | 0.280 |
Why?
|
| Mice | 24 | 2025 | 18301 | 0.270 |
Why?
|
| Liver | 9 | 2026 | 1796 | 0.260 |
Why?
|
| Sequence Analysis, Protein | 2 | 2004 | 48 | 0.260 |
Why?
|
| Binding Sites | 7 | 2014 | 1133 | 0.260 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 1722 | 0.240 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 192 | 0.240 |
Why?
|
| Ribonuclease III | 2 | 2025 | 100 | 0.240 |
Why?
|
| Biomarkers, Tumor | 3 | 2026 | 1586 | 0.230 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 125 | 0.230 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 160 | 0.230 |
Why?
|
| Genome, Human | 3 | 2021 | 1321 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2015 | 992 | 0.220 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2025 | 20 | 0.220 |
Why?
|
| Acrylamides | 1 | 2025 | 28 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 1011 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 597 | 0.220 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 58 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2026 | 223 | 0.210 |
Why?
|
| Glypicans | 1 | 2024 | 36 | 0.210 |
Why?
|
| Receptors, Ghrelin | 1 | 2024 | 30 | 0.210 |
Why?
|
| Urinary Catheterization | 1 | 2024 | 72 | 0.210 |
Why?
|
| Wound Healing | 2 | 2025 | 490 | 0.210 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2025 | 137 | 0.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 91 | 0.200 |
Why?
|
| Separase | 2 | 2014 | 28 | 0.200 |
Why?
|
| Interleukin-15 | 1 | 2024 | 104 | 0.200 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2015 | 223 | 0.200 |
Why?
|
| Immunophenotyping | 1 | 2024 | 332 | 0.200 |
Why?
|
| Germinal Center | 4 | 2013 | 36 | 0.200 |
Why?
|
| Cell Survival | 6 | 2025 | 826 | 0.200 |
Why?
|
| Rats, Wistar | 1 | 2024 | 299 | 0.200 |
Why?
|
| RNA, Untranslated | 2 | 2021 | 109 | 0.200 |
Why?
|
| Carcinoma | 1 | 2026 | 291 | 0.200 |
Why?
|
| Piperidines | 1 | 2025 | 223 | 0.190 |
Why?
|
| Protons | 2 | 2021 | 94 | 0.190 |
Why?
|
| Catheter-Related Infections | 1 | 2024 | 146 | 0.180 |
Why?
|
| Child, Preschool | 9 | 2026 | 15110 | 0.180 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 268 | 0.180 |
Why?
|
| Signal Transduction | 7 | 2025 | 4686 | 0.180 |
Why?
|
| Sex Characteristics | 1 | 2024 | 323 | 0.180 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 4697 | 0.180 |
Why?
|
| Prognosis | 7 | 2024 | 4886 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 75 | 0.180 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 2021 | 9 | 0.170 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 17 | 0.170 |
Why?
|
| RNA Interference | 2 | 2014 | 491 | 0.170 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 664 | 0.170 |
Why?
|
| Cell Death | 2 | 2019 | 224 | 0.170 |
Why?
|
| Consensus Sequence | 2 | 2015 | 54 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2021 | 26 | 0.170 |
Why?
|
| B-Lymphocytes | 4 | 2013 | 509 | 0.160 |
Why?
|
| DNA Copy Number Variations | 3 | 2026 | 1029 | 0.160 |
Why?
|
| Clonal Evolution | 1 | 2020 | 47 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 960 | 0.160 |
Why?
|
| Amish | 1 | 2020 | 11 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 358 | 0.150 |
Why?
|
| Base Sequence | 5 | 2018 | 2730 | 0.150 |
Why?
|
| Atovaquone | 1 | 2019 | 11 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1545 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 342 | 0.150 |
Why?
|
| Linear Energy Transfer | 1 | 2019 | 7 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2022 | 377 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 369 | 0.150 |
Why?
|
| DNA End-Joining Repair | 1 | 2019 | 33 | 0.150 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 573 | 0.150 |
Why?
|
| Compulsive Behavior | 1 | 2019 | 45 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2019 | 60 | 0.150 |
Why?
|
| Homologous Recombination | 1 | 2019 | 97 | 0.150 |
Why?
|
| Child | 8 | 2026 | 26341 | 0.150 |
Why?
|
| Photons | 1 | 2019 | 60 | 0.150 |
Why?
|
| Methamphetamine | 1 | 2019 | 47 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 142 | 0.140 |
Why?
|
| Piperazines | 1 | 2021 | 265 | 0.140 |
Why?
|
| AIDS Dementia Complex | 1 | 2019 | 20 | 0.140 |
Why?
|
| Vaccination | 1 | 2024 | 1060 | 0.140 |
Why?
|
| Down Syndrome | 1 | 2022 | 233 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 740 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 502 | 0.140 |
Why?
|
| Male | 22 | 2026 | 64957 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2021 | 336 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 133 | 0.140 |
Why?
|
| HIV Infections | 2 | 2022 | 2049 | 0.140 |
Why?
|
| Fetal Hemoglobin | 1 | 2018 | 27 | 0.140 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2018 | 31 | 0.140 |
Why?
|
| Erythroid Cells | 1 | 2018 | 23 | 0.140 |
Why?
|
| Encephalitis | 1 | 2019 | 122 | 0.140 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 25 | 0.140 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2018 | 20 | 0.140 |
Why?
|
| Antigenic Variation | 1 | 2018 | 37 | 0.130 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 65 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 43 | 0.130 |
Why?
|
| Atazanavir Sulfate | 1 | 2017 | 6 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 757 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 338 | 0.130 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 2323 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 200 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 357 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 438 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 104 | 0.120 |
Why?
|
| Tyrosinemias | 1 | 2016 | 7 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 722 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 227 | 0.120 |
Why?
|
| Female | 20 | 2026 | 70963 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2021 | 825 | 0.120 |
Why?
|
| Rats, Transgenic | 3 | 2022 | 17 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 710 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2019 | 282 | 0.120 |
Why?
|
| Quinazolines | 1 | 2017 | 176 | 0.120 |
Why?
|
| Models, Biological | 3 | 2018 | 1371 | 0.120 |
Why?
|
| Metformin | 1 | 2018 | 174 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2019 | 401 | 0.120 |
Why?
|
| Genomics | 3 | 2018 | 1621 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2003 | 1559 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 20 | 0.120 |
Why?
|
| Nanog Homeobox Protein | 1 | 2015 | 27 | 0.110 |
Why?
|
| HIV-1 | 1 | 2019 | 490 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 619 | 0.110 |
Why?
|
| Apoptosis | 5 | 2021 | 1827 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 533 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 96 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 895 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 83 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1272 | 0.100 |
Why?
|
| Gene Editing | 1 | 2016 | 238 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 10103 | 0.100 |
Why?
|
| Rats | 4 | 2024 | 3370 | 0.100 |
Why?
|
| Hippocampus | 1 | 2019 | 806 | 0.100 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 317 | 0.100 |
Why?
|
| Epithelium | 1 | 2014 | 335 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 165 | 0.100 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2024 | 81 | 0.090 |
Why?
|
| RNA, Transfer | 1 | 2013 | 57 | 0.090 |
Why?
|
| Obesity | 1 | 2024 | 2426 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 235 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 750 | 0.090 |
Why?
|
| Software | 2 | 2009 | 733 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2012 | 51 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2014 | 556 | 0.090 |
Why?
|
| Neurons | 1 | 2021 | 1979 | 0.090 |
Why?
|
| Cell Proliferation | 5 | 2019 | 2465 | 0.090 |
Why?
|
| Genetic Therapy | 1 | 2016 | 713 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 421 | 0.090 |
Why?
|
| Infant | 6 | 2026 | 13352 | 0.080 |
Why?
|
| Amino Acid Motifs | 3 | 2010 | 189 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 760 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 147 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 448 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 680 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2010 | 9 | 0.080 |
Why?
|
| Genes, Regulator | 1 | 2010 | 44 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2025 | 254 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1378 | 0.080 |
Why?
|
| Protein Domains | 2 | 2023 | 252 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 252 | 0.080 |
Why?
|
| Systems Biology | 1 | 2010 | 60 | 0.080 |
Why?
|
| DNA | 1 | 2015 | 1399 | 0.080 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2009 | 5 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 950 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 21 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2010 | 1363 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 378 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2024 | 5063 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2602 | 0.070 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 83 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 4738 | 0.070 |
Why?
|
| Databases, Genetic | 3 | 2018 | 504 | 0.070 |
Why?
|
| Data Collection | 1 | 2009 | 370 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 371 | 0.070 |
Why?
|
| Pancreas | 2 | 2025 | 217 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 299 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 151 | 0.060 |
Why?
|
| Gene Expression | 3 | 2019 | 1481 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 457 | 0.060 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2007 | 28 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 975 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2018 | 585 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2017 | 263 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 972 | 0.060 |
Why?
|
| Heterografts | 2 | 2017 | 191 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1591 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2026 | 3711 | 0.060 |
Why?
|
| Recurrence | 2 | 2023 | 1489 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1419 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2026 | 136 | 0.060 |
Why?
|
| Vertebrates | 1 | 2005 | 36 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2019 | 229 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2019 | 3819 | 0.050 |
Why?
|
| Protein Binding | 4 | 2010 | 1652 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1306 | 0.050 |
Why?
|
| Exons | 3 | 2016 | 759 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2018 | 2885 | 0.050 |
Why?
|
| Ghrelin | 1 | 2024 | 58 | 0.050 |
Why?
|
| Thermogenesis | 1 | 2024 | 57 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2004 | 277 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 60 | 0.050 |
Why?
|
| Adipose Tissue, Brown | 1 | 2024 | 89 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 775 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2024 | 167 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 89 | 0.050 |
Why?
|
| Vincristine | 1 | 2024 | 187 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2904 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 412 | 0.050 |
Why?
|
| Pedigree | 2 | 2020 | 1677 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2015 | 292 | 0.050 |
Why?
|
| Phenotype | 2 | 2026 | 4497 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 16 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 192 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2024 | 765 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2022 | 65 | 0.040 |
Why?
|
| Eating | 1 | 2024 | 377 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 226 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2018 | 716 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2026 | 3436 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2021 | 9 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2014 | 414 | 0.040 |
Why?
|
| ARNTL Transcription Factors | 1 | 2021 | 45 | 0.040 |
Why?
|
| Species Specificity | 2 | 2013 | 470 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2003 | 729 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 61 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 377 | 0.040 |
Why?
|
| Adolescent | 3 | 2026 | 20987 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 28601 | 0.040 |
Why?
|
| HIV | 1 | 2022 | 174 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 431 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 127 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2021 | 66 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 387 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2022 | 317 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2003 | 516 | 0.040 |
Why?
|
| Carbon | 1 | 2021 | 101 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1205 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2304 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 786 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 236 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 689 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 700 | 0.040 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Aged | 4 | 2024 | 21025 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2022 | 330 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2009 | 16 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 33 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2022 | 348 | 0.040 |
Why?
|
| Gene Drive Technology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1826 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2020 | 178 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 418 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 214 | 0.040 |
Why?
|
| gamma-Globins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Methylation | 1 | 2019 | 199 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 137 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2018 | 42 | 0.030 |
Why?
|
| K562 Cells | 1 | 2018 | 97 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 1211 | 0.030 |
Why?
|
| Adenosine | 1 | 2019 | 116 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2014 | 594 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 325 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3464 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 177 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 362 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 133 | 0.030 |
Why?
|
| Cytochromes | 1 | 2017 | 7 | 0.030 |
Why?
|
| Adult | 4 | 2024 | 31282 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2019 | 235 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 276 | 0.030 |
Why?
|
| Heterozygote | 1 | 2020 | 737 | 0.030 |
Why?
|
| Chimera | 1 | 2017 | 79 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 157 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2017 | 45 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 215 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 394 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 209 | 0.030 |
Why?
|
| Nitrobenzoates | 1 | 2016 | 6 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 254 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1239 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 497 | 0.030 |
Why?
|
| Cyclohexanones | 1 | 2016 | 18 | 0.030 |
Why?
|
| United States | 2 | 2024 | 12072 | 0.030 |
Why?
|
| Hydrolases | 1 | 2016 | 61 | 0.030 |
Why?
|
| Inflammation | 1 | 2024 | 1489 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 546 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1105 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1483 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2016 | 105 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 37 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2024 | 17753 | 0.030 |
Why?
|
| Histones | 1 | 2019 | 541 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1064 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 776 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2016 | 232 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 732 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 334 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 154 | 0.030 |
Why?
|
| Weaning | 1 | 2014 | 52 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 544 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 358 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 2833 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 133 | 0.020 |
Why?
|
| Decision Trees | 1 | 2013 | 57 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2013 | 100 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 93 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 573 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 142 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2013 | 138 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 410 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 80 | 0.020 |
Why?
|
| Replication Protein A | 1 | 2013 | 10 | 0.020 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 34 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 743 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 566 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3360 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 1013 | 0.020 |
Why?
|
| Risk Factors | 1 | 2026 | 11074 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 1077 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 2595 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2012 | 200 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 645 | 0.020 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2010 | 7 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 801 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 67 | 0.020 |
Why?
|
| DNA Probes | 1 | 2009 | 117 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5196 | 0.020 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2009 | 19 | 0.020 |
Why?
|
| Mitosis | 1 | 2010 | 191 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 511 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6196 | 0.020 |
Why?
|
| Haplorhini | 1 | 2009 | 107 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2009 | 36 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 195 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 2114 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 545 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3385 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3359 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 2326 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 2395 | 0.020 |
Why?
|
| Dogs | 1 | 2009 | 613 | 0.020 |
Why?
|
| DNA Replication | 1 | 2010 | 355 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12936 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 633 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 188 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 344 | 0.020 |
Why?
|
| Systems Integration | 1 | 2007 | 24 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 423 | 0.010 |
Why?
|
| Aging | 1 | 2013 | 1242 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 644 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 358 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2005 | 116 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 104 | 0.010 |
Why?
|
| Testis | 1 | 2007 | 389 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 12 | 0.010 |
Why?
|
| Lung | 1 | 2012 | 1535 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 500 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 483 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1833 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 749 | 0.010 |
Why?
|
| Myocardium | 1 | 2007 | 852 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 440 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 981 | 0.010 |
Why?
|